International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02844517
• Other study ID #: 19068
• Secondary ID: UC4DK108483
• Status: Completed
• Phase: N/A
• Start date: November 2016
• Est. completion date: October 2017

Study information

• Verified date: May 2018
• Source: University of Virginia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is for clinical staff to gain experience using the proposed artificial pancreas system named inControl and the inControl Cloud and assess 24/7 in-home usability prior to initiating a large randomized controlled trial.

Description:

Participation in this study will require 5 study visits over 2-4 weeks.

• Visit 1: screening/enrollment visit to assess study eligibility.

• Visit 2: continuous glucose monitor (CGM) training and initiation session based upon current or prior use of a CGM; if subject doesn't currently use a CGM, subject will be trained and may be asked to wear the CGM at home for 1 week.

• Visit 3: subjects will be taught how to use the study insulin pump.

• Visit 4: subjects will be trained on the use of inControl and wear it at home for 14 days.

• Visit 5: subjects will return study equipment and to complete questionnaire.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 74 Years

Eligibility

Inclusion Criteria

1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year

2. Use of an insulin pump for at least 6 months with established parameters for basal rate(s), carbohydrate ratio(s) and insulin sensitivity factor(s) for at least 3 months.

3. Age 14.0 to <75.0 years

4. HbA1c level <10.5% at screening

5. For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study. Also, subjects who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.

6. Have care partner committed to participating in all training activities, knowledgeable at all times of the participants location, and being present and available to provide assistance when the system is being used at night

7. Willingness, if using the closed-loop system, to stop closed-loop when taking acetaminophen and avoid closed-loop for at least 4 hours afterward

8. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use

9. Willingness to establish network connectivity on a daily basis either via local Wi-Fi network or via a study-provided cellular service

10. Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol

11. Currently using no insulins other than one of the following rapid-acting insulins at the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine (Apidra)

12. Total daily insulin dose (TDD) less than 100 U/day

Exclusion Criteria

1. More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment

2. More than one episode of severe hypoglycemia involving seizure of loss of consciousness in the 6 months prior to enrollment

3. Medical need for chronic acetaminophen

4. Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals).

5. Hemophilia or any other bleeding disorder

6. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk

7. Participation in another pharmaceutical or device trial at the time of enrollment or during the study

8. Employed by, or having immediate family members employed by TypeZero Technologies, LLC

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Device:
• Artificial Pancreas
Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.

Locations

Country	Name	City	State
France	University of Montpellier	Montpellier
Italy	University of Padova	Padova
Netherlands	Academic Medical Center	Amsterdam
United States	Barbara Davis Center, University of Colorado	Aurora	Colorado
United States	Harvard University (Joslin Diabetes Center)	Boston	Massachusetts
United States	University of Virginia Center for Diabetes Technology	Charlottesville	Virginia
United States	Mt. Sinai	New York	New York
United States	Mayo Clinic	Rochester	Minnesota
United States	William Sansum Diabetes Center	Santa Barbara	California
United States	Stanford University	Stanford	California

Sponsors (7)

Lead Sponsor	Collaborator
University of Virginia	DexCom, Inc., Jaeb Center for Health Research, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Roche Diagnostic Ltd., Tandem Diabetes Care, Inc., TypeZero Technologies, LLC

Countries where clinical trial is conducted

United States,  France,  Italy,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.		2 weeks